← feed

Is NCT02088684 results overdue?

Yes — results are overdue. Primary completion was 2018-04-17; the FDAAA-801 reporting deadline (2019-04-17) passed 2668 days ago and no results are posted on ClinicalTrials.gov.

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

NCT IDNCT02088684 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-04-17 (ACTUAL)
Reporting deadline2019-04-17 (completion + 365d)
Days overdue2668
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 fe68598f3dd29f79… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT02088684. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →